Mirus

Mirus Bio has introduced the TransIT-X2 dynamic delivery system.
According to the company, the polymeric nucleic acid-delivery system can be used for independent or simultaneous delivery of DNA and siRNA to a variety of cell types.

Arrowhead Research's top executive this week broke out details on the company's efforts to move its RNAi-based hepatitis B virus treatment ARC-520 into the clinic, stating that the firm will run two phase I trials in order to speed up the generation of key human data.

Arrowhead Research last week released new preclinical data on its lead drug candidate, the hepatitis B virus treatment ARC-520, reporting that the agent could trigger up to multi-log reductions in the levels of circulating viral antigens, while lowering levels of the virus' repli

Arrowhead Research announced this week that it has signed a RNAi services agreement with Germany's Axolabs, bringing together the US and European halves of Roche's former RNA therapeutics operations that were divested by the biopharmaceutical giant in 2010.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.